Research Grade Diridavumab
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants) .
Product Specifications
Product Name Alternative
CR-6261, CR6261, CAS: 1393659-46-5
Accession Number
P03455
Expression System
Mammalian Cells
Reactivity
Influenza A virus
Applications
Research Grade Biosimilar
Stability
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Notes
For research use only. Not suitable for clinical or therapeutic use.
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
